<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article8</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/GUSTO" style="display:block; margin-bottom:10px;">GUSTO Original</a></li>
<h2><strong>GUSTO</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with acute myocardial infarction undergoing thrombolytic therapy, which regimen improves survival: streptokinase with subcutaneous heparin, streptokinase with intravenous heparin, accelerated tissue plasminogen activator (t-PA) with intravenous heparin, or a combination of streptokinase plus t-PA with intravenous heparin?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with acute myocardial infarction, accelerated t-PA combined with intravenous heparin provided a survival benefit over standard thrombolytic regimens with streptokinase.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, open-label trial<br/>
- N=41,021<br/>
- Four treatment groups:<br/>
  1. Streptokinase with subcutaneous heparin<br/>
  2. Streptokinase with intravenous heparin<br/>
  3. Accelerated t-PA with intravenous heparin<br/>
  4. Combination streptokinase plus t-PA with intravenous heparin<br/>
- Setting: 1081 hospitals in 15 countries<br/>
- Enrollment: December 1990 to February 1993<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Patients with symptoms of myocardial infarction of less than 6 hours' duration with ST-segment elevation<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Streptokinase (1.5 million U) with either subcutaneous or intravenous heparin, or<br/>
- Accelerated t-PA with intravenous heparin, or<br/>
- Combined streptokinase plus t-PA with intravenous heparin<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary: 30-day mortality<br/>
- Secondary: Combined endpoints of death and nonfatal stroke, death and nonfatal hemorrhagic stroke, and death and nonfatal disabling stroke<br/>
- Tertiary: Stroke and bleeding complications<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open-label design without a placebo group may introduce bias<br/>
- The cost and complexity of administering t-PA may limit its widespread use<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Supported by a combined grant from Bayer, CIBA-Corning, Genentech, ICI Pharmaceuticals, and Sanofi Pharmaceuticals<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full article, as published in The New England Journal of Medicine, provides a detailed account of the study methods, populations, interventions, and outcomes.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
